Mark Payton

Dr Mark Payton has previously held senior roles with companies such as GlaxoSmithKline, Glaxo Wellcome and Biogen (now Biogen Idec) and is a Senior Adviser to The Cleveland-based Harrington Project for Discovery and Development. He was formerly CEO of Oxagen Ltd and Atopix Therapeutics and also co-founder of Orca Pharmaceuticals. He brings extensive experience of growing organisations across all aspects of the biotech environment.